Revolution Medicines Appoints Alan Sandler, M.D. As First Chief Development Officer And Names New Regional General Managers In The U.S. And Europe

Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, has announced important additions to its leadership team. The company has appointed Alan Sandler, M.D., to the newly established position of chief development officer. Alongside this, it has also appointed regional general managers in the United States and Europe to strengthen its commercial readiness.

Dr. Sandler brings with him decades of experience in oncology research and drug development. He joins Revolution Medicines from ALX Oncology, where he served as chief medical officer. Prior to that, he held the role of executive vice president and chief medical officer at Mirati Therapeutics, where he guided clinical development efforts until the company was acquired by Bristol Myers Squibb. 

He also served as president and head of global development, Oncology at Zai Lab Limited. Earlier in his career, he was part of Genentech, a member of the Roche Group, where he played a key role in advancing several oncology programs. In addition to his contributions in the biopharmaceutical industry, Dr. Sandler has held significant academic and clinical leadership positions, including division chief of Hematology/Oncology at Oregon Health and Science University, medical director of Thoracic Oncology at Vanderbilt University, and medical director of the Thoracic Oncology Program at Indiana University.

In parallel with this appointment, Revolution Medicines has named two senior leaders to oversee its commercial strategy in major markets. Alicia Gardner has been appointed as senior vice president and general manager for the U.S. region, while Gerwin Winter will serve as senior vice president and general manager for the European region. 

Both leaders will play critical roles in preparing for the potential regulatory approvals and commercial launches of the company’s lead investigational therapy, daraxonrasib, for patients with RAS-driven cancers such as pancreatic ductal adenocarcinoma. They will also help guide the introduction of additional innovative therapies from the company’s pipeline designed to address the needs of patients living with RAS-addicted cancers.